Kuang Tianrui, Ma Wangbin, Zhang Jiacheng, Yu Jia, Deng Wenhong, Dong Keshuai, Wang Weixing
Department of General Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, China.
Central Laboratory, Renmin Hospital of Wuhan University, Wuhan 430060, China.
Cancers (Basel). 2023 Nov 7;15(22):5310. doi: 10.3390/cancers15225310.
Hepatocellular carcinoma (HCC) is a widespread and impactful cancer which has pertinent implications worldwide. Although most cases of HCC are typically diagnosed in individuals aged ≥60 years, there has been a notable rise in the occurrence of HCC among younger patients. However, there is a scarcity of precise prognostic models available for predicting outcomes in these younger patients. A retrospective analysis was conducted to investigate early-onset hepatocellular carcinoma (EO-LIHC) using data from the Surveillance, Epidemiology, and End Results (SEER) database from 2004 to 2018. The analysis included 1392 patients from the SEER database and our hospital. Among them, 1287 patients from the SEER database were assigned to the training cohort ( = 899) and validation cohort 1 ( = 388), while 105 patients from our hospital were assigned to validation cohort 2. A Cox regression analysis showed that age, sex, AFP, grade, stage, tumor size, surgery, and chemotherapy were independent risk factors. The nomogram developed in this study demonstrated its discriminatory ability to predict the 1-, 3-, and 5-year overall survival (OS) rates in EO-LIHC patients based on individual characteristics. Additionally, a web-based OS prediction model specifically tailored for EO-LIHC patients was created and validated. Overall, these advancements contribute to improved decision-making and personalized care for individuals with EO-LIHC.
肝细胞癌(HCC)是一种广泛存在且影响重大的癌症,在全球范围内都有相关影响。虽然大多数HCC病例通常在年龄≥60岁的个体中被诊断出来,但年轻患者中HCC的发病率却有显著上升。然而,目前缺乏精确的预后模型来预测这些年轻患者的预后结果。利用2004年至2018年监测、流行病学和最终结果(SEER)数据库的数据进行了一项回顾性分析,以研究早发性肝细胞癌(EO-LIHC)。该分析纳入了来自SEER数据库和我院的1392例患者。其中,来自SEER数据库的1287例患者被分配到训练队列(=899)和验证队列1(=388),而我院的105例患者被分配到验证队列2。Cox回归分析表明,年龄、性别、甲胎蛋白、分级、分期、肿瘤大小、手术和化疗是独立的危险因素。本研究开发的列线图显示了其根据个体特征预测EO-LIHC患者1年、3年和5年总生存率(OS)的判别能力。此外,还创建并验证了一个专门为EO-LIHC患者量身定制的基于网络的OS预测模型。总体而言,这些进展有助于改善EO-LIHC患者的决策制定和个性化护理。